HomeProductsBuilding BlocksHeterocyclic ScaffoldsPiperazinesX-396
Chemical structure of CAS 1365267-27-1

X-396

In Stock•Starting at $11 for 2 mg•Purity ≥ 99%
CAS No.1365267-27-1
MDL No.MFCD25976868
MFC25H25Cl2FN6O3
MW547.40
InChI KeyONPGOSVDVDPBCY-CQSZACIVSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
2 mg99%$11In Stock
5 mg99%$16In Stock
10 mg99%$24In Stock
25 mg99%$51In Stock
50 mg99%$65In Stock
100 mg99%$78In Stock
250 mg99%$157In Stock
1 g99%$436In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1365267-27-1
Product NameX-396
Heavy Atom Count37Rotatable Bond Count6
Atom Stereo Count1Bond Stereo Count0
HBA7HBD2
TPSA113.680 ŲCharge0
Exact Mass546.13492Complexity1316.52
pKa7.130XLogP4.285

Related Articles

Studies related to this compound and its mechanism of action

Ensartinib in the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real-world, retrospective study.

Asia-Pacific journal of clinical oncology • Vol. 20, Issue 6 • 2024
PMID: 38898784DOI: 10.1111/ajco.14091

Ensartinib rapidly relieves symptoms in ALK-positive patients with brain metastases.

Asian journal of surgery • Vol. 47, Issue 9 • 2024
PMID: 38749835DOI: 10.1016/j.asjsur.2024.04.171

Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.

BMC cancer • Vol. 24, Issue 1 • 2024
PMID: 38331773PMC: PMC10851546DOI: 10.1186/s12885-024-11916-4

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

Cancer research • Vol. 71, Issue 14 • 2011
PMID: 21613408PMC: PMC3138877DOI: 10.1158/0008-5472.CAN-10-3879

Documentation

Similar Products